By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno Therapeutics
Employees: n/a
Symbol: 
 



Industry
Biotechnology






Company News
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
Price Tag May Be The Challenge For Novartis AG (NVS) And Juno Therapeutics' Magical Cancer Drugs 10/8/2014 6:25:40 AM
Juno Therapeutics Appoints Hal Barron, M.D. To Board Of Directors 10/1/2014 9:09:18 AM
MabVax Therapeutics, Inc. Enters Agreements With Memorial Sloan-Kettering Cancer Center And Juno Therapeutics For Development Of Anti-Cancer Therapeutics 9/10/2014 8:14:07 AM
Fresh From Co-Founding Massively Financed Juno Therapeutics, Arch Venture Partners Banks $400 Million+ To Back New Biotechs 8/27/2014 5:58:54 AM
Already-Rich Juno Therapeutics Reels In Another $134 Million, Has Raised $300 Million In Less Than 12 Months 8/5/2014 6:17:28 AM
Cancer-Fighter Juno Therapeutics Completes $176 Million Series A Round 4/24/2014 6:28:49 AM
Clinical Trial Of Juno Therapeutics Cell Therapy Restarts 4/21/2014 7:36:27 AM
Seattle's Juno Therapeutics Pauses Trial After Patient Deaths 4/9/2014 7:07:21 AM
Juno Therapeutics Appoints Biotech Investment Banking Leader Steve Harr As CFO And Head Of Corporate Development 3/31/2014 7:45:26 AM
12
//-->